Karrels James's most recent trade in Macrogenics Inc was a trade of 150,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Macrogenics Inc | James Karrels | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Macrogenics Inc | James Karrels | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 25,000 | 25,000 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | James Karrels | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 14,999 | 0 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | James Karrels | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 14,999 | 211,827 (0%) | 0% | - | Common Stock | |
| Macrogenics Inc | James Karrels | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.71 per share. | 12 Feb 2026 | 5,790 | 206,037 (0%) | 0% | 1.7 | 9,901 | Common Stock |
| Macrogenics Inc | James Karrels | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2026 | 9,999 | 200,688 (0%) | 0% | - | Common Stock | |
| Macrogenics Inc | James Karrels | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2026 | 9,999 | 9,999 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | James Karrels | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2026 | 6,334 | 193,135 (0%) | 0% | - | Common Stock | |
| Macrogenics Inc | James Karrels | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2026 | 6,334 | 12,666 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | James Karrels | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.81 per share. | 07 Feb 2026 | 3,860 | 196,828 (0%) | 0% | 1.8 | 6,987 | Common Stock |
| Macrogenics Inc | James Karrels | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.81 per share. | 07 Feb 2026 | 2,446 | 190,689 (0%) | 0% | 1.8 | 4,427 | Common Stock |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 14,998 | 14,999 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 14,998 | 192,591 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.56 per share. | 15 Feb 2025 | 5,790 | 186,801 (0%) | 0% | 2.6 | 14,822 | Common Stock |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 113,000 | 113,000 | - | - | Employee Stock Option (right to buy) | |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 19,000 | 19,000 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 10,002 | 19,998 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 10,002 | 181,454 (0%) | 0% | - | Common Stock | |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.60 per share. | 07 Feb 2025 | 3,861 | 177,593 (0%) | 0% | 2.6 | 10,039 | Common Stock |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Sale of securities on an exchange or to another person at price $ 20.50 per share. | 04 Mar 2024 | 30,000 | 171,452 (0%) | 0% | 20.5 | 615,000 | Common Stock |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 15,003 | 206,779 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | Karrels James | SVP, CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 15,003 | 29,997 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Karrels James | SVP, CFO and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.40 per share. | 15 Feb 2024 | 5,327 | 201,452 (0%) | 0% | 17.4 | 92,690 | Common Stock |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 80,000 | 80,000 | - | - | Employee Stock Option (right to buy) | |
| Macrogenics Inc | Karrels James | SVP, CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 30,000 | 30,000 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 180,000 | 180,000 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 45,000 | 45,000 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Purchase of securities on an exchange or from another person at price $ 2.47 per share. | 15 Jun 2022 | 40,000 | 191,776 (0%) | 0% | 2.5 | 98,800 | Common Stock |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2022 | 8,316 | 0 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.51 per share. | 28 Mar 2022 | 8,316 | 151,776 (0%) | 0% | 1.5 | 12,557 | Common Stock |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 140,000 | 140,000 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | James Karrels | SVP, CFO and Secretary | Sale of securities on an exchange or to another person at price $ 33.00 per share. | 22 Mar 2021 | 15,000 | 143,460 (0%) | 0% | 33 | 495,000 | Common Stock |